Bank of Montreal’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $361K | Sell |
24,933
-517
| -2% | -$7.41K | ﹤0.01% | 2553 |
|
|
2025
Q4 | $362K | Hold |
25,450
| – | – | ﹤0.01% | 2466 |
|
|
2025
Q3 | $201K | Buy |
25,450
+392
| +2% | +$2.79K | ﹤0.01% | 2785 |
|
|
2025
Q2 | $144K | Buy |
+25,058
| New | +$162K | ﹤0.01% | 2901 |
|
|
2024
Q3 | – | Sell |
-107,369
| Closed | -$1.1M | – | 3965 |
|
|
2024
Q2 | $1.1M | Buy |
+107,369
| New | +$1.1M | ﹤0.01% | 1976 |
|
|
2023
Q3 | – | Sell |
-290,517
| Closed | -$3.8M | – | 3950 |
|
|
2023
Q2 | $3.8M | Sell |
290,517
-10,319
| -3% | -$122K | ﹤0.01% | 1466 |
|
|
2023
Q1 | $3.4M | Buy |
300,836
+11,420
| +4% | +$141K | ﹤0.01% | 1412 |
|
|
2022
Q4 | $3.55M | Sell |
289,416
-1,094
| -0.4% | -$12.3K | ﹤0.01% | 1483 |
|
|
2022
Q3 | $3.04K | Sell |
290,510
-340,213
| -54% | -$3.79M | ﹤0.01% | 1610 |
|
|
2022
Q2 | $7.01K | Buy |
630,723
+270,318
| +75% | +$2.23M | ﹤0.01% | 1226 |
|
|
2022
Q1 | $3.47M | Sell |
360,405
-8,672
| -2% | -$81.3K | ﹤0.01% | 1644 |
|
|
2021
Q4 | $4.45M | Sell |
369,077
-123,824
| -25% | -$1.38M | ﹤0.01% | 1279 |
|
|
2021
Q3 | $4.77M | Buy |
492,901
+239,534
| +95% | +$2.45M | ﹤0.01% | 1658 |
|
|
2021
Q2 | $2.67M | Buy |
253,367
+12,054
| +5% | +$118K | ﹤0.01% | 1914 |
|
|
2021
Q1 | $2.24M | Buy |
241,313
+3,993
| +2% | +$61.8K | ﹤0.01% | 1740 |
|
|
2020
Q4 | $5.38M | Buy |
237,320
+174,927
| +280% | +$3.58M | ﹤0.01% | 1339 |
|
|
2020
Q3 | $897K | Sell |
62,393
-9,940
| -14% | -$145K | ﹤0.01% | 2032 |
|
|
2020
Q2 | $1.15M | Buy |
72,333
+71,575
| +9,443% | +$872K | ﹤0.01% | 1855 |
|
|
2020
Q1 | $7K | Sell |
758
-92,640
| -99% | -$881K | ﹤0.01% | 3594 |
|
|
2019
Q4 | $910K | Buy |
93,398
+70,868
| +315% | +$649K | ﹤0.01% | 2330 |
|
|
2019
Q3 | $181K | Sell |
22,530
-117,642
| -84% | -$1.28M | ﹤0.01% | 2971 |
|
|
2019
Q2 | $1.75M | Buy |
140,172
+46,328
| +49% | +$588K | ﹤0.01% | 1766 |
|
|
2019
Q1 | $1.28M | Buy |
93,844
+90,416
| +2,638% | +$1.1M | ﹤0.01% | 1922 |
|
|
2018
Q4 | $33K | Buy |
3,428
+1,855
| +118% | +$20.4K | ﹤0.01% | 3448 |
|
|
2018
Q3 | $19K | Sell |
1,573
-1,341
| -46% | -$18.8K | ﹤0.01% | 3721 |
|
|
2018
Q2 | $45K | Buy |
2,914
+622
| +27% | +$9.4K | ﹤0.01% | 3451 |
|
|
2018
Q1 | $34K | Hold |
2,292
| – | – | ﹤0.01% | 3380 |
|
|
2017
Q4 | $33K | Buy |
+2,292
| New | +$31.5K | ﹤0.01% | 3418 |
|
|
2014
Q3 | – | Sell |
-740
| Closed | -$2K | – | 4145 |
|
|
2014
Q2 | $2K | Buy |
+740
| New | +$1.74K | ﹤0.01% | 4488 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Bank of Montreal's FOLD Position: Q1 2026 in Review
Bank of Montreal reduced its Amicus Therapeutics (FOLD) stake by 2% in Q1 2026, selling an estimated $7.41K and leaving 24,933 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #2553.
Bank of Montreal first reported a position in FOLD in Q2 2014 and has held it in 29 quarters since. The position peaked at $5.38M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Bank of Montreal held 24,933 shares of Amicus Therapeutics worth $361K as of Q1 2026.
- Bank of Montreal sold 517 Amicus Therapeutics shares in Q1 2026, an estimated $7.41K.
- Amicus Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #2553 holding.
- Bank of Montreal first reported a position in Amicus Therapeutics in Q2 2014 and has held it in 29 quarters since.
- Bank of Montreal's Amicus Therapeutics position peaked at $5.38M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.